National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2016 (No. 9) (PB 92 of 2016) (Cth)

PB 92 of 2016

National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2016 (No. 9)

National Health Act 1953

I, PENNY SHAKESPEARE, First Assistant Secretary, Pharmaceutical Benefits Division, Department of Health, delegate of the Minister for Health and Aged Care, make this Instrument under subsection 84AAA(2) of the National Health Act 1953.

Dated 26 October                           2016

PENNY SHAKESPEARE
First Assistant Secretary
Pharmaceutical Benefits Division

Department of Health

___________________________________________________________________________

Amendment instrument – Pharmaceutical benefits – early supply

1          Name of Instrument

(1)      This Instrument is the National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2016 (No. 9)

(2)This Instrument may also be cited as PB 92 of 2016.

2          Commencement

This Instrument commences on 1 November 2016.

3          Amendment of PB 120 of 2015

Schedule 1 amends the National Health (Pharmaceutical benefits—early supply) Instrument 2015 (PB 120 of 2015).

Schedule 1        Amendments

1. Schedule 1, after entry for Apixaban in the form Tablet 5 mg [Maximum Quantity: 60]

   insert:

Armodafinil	Tablet 50 mg	20	60	5
Armodafinil	Tablet 150 mg	20	30	5
Armodafinil	Tablet 250 mg	20	30	5

1. Schedule 1, after entry for Auranofin in the form Tablet 3 mg [Maximum Quantity: 60]

   insert:

Auranofin Tablet 3 mg 20 100 3

1. Schedule 1, entry for Imatinib

   insert as first item in the columns in the order indicated:

Imatinib	Capsule 100 mg (as mesilate)	20	60	2
Imatinib	Capsule 100 mg (as mesilate)	20	60	5
Imatinib	Capsule 400 mg (as mesilate)	20	30	2
Imatinib	Capsule 400 mg (as mesilate)	20	30	5

1. Schedule 1, entry for Imatinib in each of the forms: Tablet 100 mg (as mesylate); and Tablet 400 mg (as mesylate)

   omit from the column headed “Form”:                 mesylate     substitute:      mesilate

2. Schedule 1, after entry for Reboxetine in the form Tablet 4 mg (as mesilate)

   insert:

Ribavirin Tablet 200 mg 20 28 5

1. Schedule 1, entry for Ribavirin in the form Tablet 600 mg [Maximum Number of Repeats: 2]

   omit the first instance:

Ribavirin Tablet 600 mg 20 28 2

1. Schedule 1, after entry for Ruxolitinib in the form Tablet 5 mg [Maximum Number of Repeats: 5]

   insert:

Ruxolitinib	Tablet 10 mg	20	56	0
Ruxolitinib	Tablet 10 mg	20	56	5